Are peptides legal in the US, and is it legal to import them?

The short answer

Peptides occupy a legal gray zone in the United States. A handful are FDA-approved prescription drugs (the GLP-1s like semaglutide). Most of the "research peptides" sold online — BPC-157, CJC-1295, TB-500, and similar — are not approved for human use, are labeled "research use only," and sit in an unregulated market. Buying or importing them carries real legal and safety risk.

Evidence tier: Tier 1 for the regulatory framework (FDA statutes and published policy). Educational content, not legal or medical advice.

The key points, up front:

• A few peptides are fully legal prescription drugs — semaglutide (Ozempic/Wegovy), tirzepatide, and other GLP-1s have FDA approval.
• Most "research peptides" are unapproved drugs — selling them for human use is illegal, and the "research use only" label is not a legal loophole.
• Importing unapproved peptides for personal use is, in most cases, illegal — the FDA exercises narrow enforcement discretion that gray-market orders rarely meet.
• Compounding has its own rules — sections 503A and 503B govern pharmacy-compounded peptides, and the FDA flagged many popular peptides (including BPC-157 and CJC-1295) over safety concerns.

For the deeper regulatory background, see our peptide legal status cornerstone.

Are peptides legal in the US?

Evidence tier: 1 — based on the Federal Food, Drug, and Cosmetic Act and published FDA policy.

The honest answer is "it depends entirely on which peptide and what you do with it." The word "peptide" is just a chemistry term for a short chain of amino acids; it tells you nothing about legal status. Legality in the US turns on FDA approval and on how a substance is marketed and used.

At one end, several peptides are approved prescription drugs. The GLP-1 receptor agonists — semaglutide (Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), liraglutide — are fully legal medicines, prescribed by clinicians and dispensed by pharmacies. Insulin is a peptide too. These have been through clinical trials, carry FDA labeling, and are manufactured under strict quality rules.

At the other end sit the "research peptides" — BPC-157, CJC-1295, ipamorelin, TB-500, GHK-Cu, and dozens more. None of these is an FDA-approved drug for human use. They are typically sold online as powders labeled "for research use only" or "not for human consumption." That label is doing legal work: vendors use it to argue they are selling laboratory reagents, not drugs. But the FDA looks at intended use, not label wording. The moment a peptide is marketed or sold for people to inject, it becomes an unapproved new drug under the Federal Food, Drug, and Cosmetic Act, and selling it that way is illegal. The FDA's position on unapproved and compounded drug products is consistent: such products are "not FDA-approved," meaning the agency "does not review their safety, effectiveness or quality before they are marketed" (FDA, Understanding the Risks of Compounded Drugs).

So "are peptides legal" has no single answer. A short list is legal as prescription medicine. The large, popular gray market is not legal to sell for human use — and that is the reality behind most searches for "legal peptides."

Is it legal to import peptides for personal use?

Evidence tier: 1 — directly from FDA's published Personal Importation policy.

This is one of the most-searched legality questions, and the answer is uncomfortable for the gray market: in most cases, no, it is not clearly legal.

The FDA's Personal Importation policy is explicit. "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use because these products purchased from other countries often have not been approved by the FDA for use and sale in the U.S. If a drug is approved for use in another country but is an unapproved new drug in the U.S. it is illegal to import" (FDA, Personal Importation).

The agency does describe situations where its personnel "may consider a more permissive decision" — but the conditions are narrow. For a product treating a serious condition, the FDA looks for: no effective domestic treatment available, no commercialization to US residents, no unreasonable risk, a written affirmation that the product is for personal use, a quantity generally not more than a three-month supply, and either the name of a US-licensed doctor overseeing treatment or evidence the treatment was begun abroad (FDA, Personal Importation).

A bulk order of research-grade BPC-157 from an overseas vendor, with no prescription and no overseeing physician, does not come close to meeting those conditions. Critically, this is enforcement discretion, not a legal right — the FDA may still refuse a shipment, and it explicitly refuses personal importations when a product is on an import alert, appears intended for commercial distribution, or appears to present a serious risk to health (FDA, Personal Importation). In practice, customs can and does detain or destroy peptide shipments. The "research use only" label offers no protection at the border, because what matters is intended use, not the words on the vial.

If you want a buyer's-eye view of sourcing and the risks involved, our peptide safety and sourcing guide walks through what actually arrives versus what is advertised.

Compounding, 503A, and 503B: where the rules get specific

Evidence tier: 1 — Drug Quality and Security Act and FDA compounding policy.

There is a narrow, legitimate channel through which some peptides reach patients: pharmacy compounding. This is also where the legal picture has been shifting fastest, so it deserves precision.

Compounding is regulated under two sections of federal law added or clarified by the Drug Quality and Security Act of 2013. Section 503A covers traditional pharmacies that compound based on individual, patient-specific prescriptions. Section 503B covers "outsourcing facilities," which are subject to current good manufacturing practice (CGMP) requirements and FDA inspection, and can produce larger batches (FDA, Human Drug Compounding Laws). Importantly, compounded drugs of either kind are still not FDA-approved — the agency does not review them for safety, effectiveness, or quality before they reach patients, and it has investigated many serious injuries linked to poor-quality compounded products (FDA, Understanding the Risks of Compounded Drugs).

For a peptide to be compounded under 503A, its bulk drug substance generally needs to be on an approved list, or be a component of an approved drug, or appear in a US pharmacopoeia monograph. In 2023, the FDA placed more than a dozen popular peptides — including BPC-157 and CJC-1295 — into a category effectively barring them from compounding, citing significant safety concerns such as immunogenicity (the risk the body mounts an immune response), peptide-related impurities, and limited human clinical data. The agency's stated concern about CJC-1295, for example, centered on the immunogenicity risk of the injectable form and the sensitivity of peptide quality to the manufacturing process.

The picture is genuinely in flux. In 2026, the FDA moved several of these peptides out of that "do not compound" category, and the Pharmacy Compounding Advisory Committee (PCAC) — the body that advises the FDA on which bulk substances belong on the compounding lists — is scheduled to formally review peptides including BPC-157 and TB-500 at its mid-2026 meeting (FDA, Pharmacy Compounding Advisory Committee (PCAC)). Two cautions matter here. First, removal from a restriction category is not the same as FDA approval; it governs compounding eligibility only and confers no validated indication, dose, or proven benefit. Second, none of this makes an online "research use only" powder a legal drug — compounding legality lives inside licensed pharmacies, not in mail-order research-chemical sales.

Is CJC-1295 legal? And what about BPC-157?

Evidence tier: 1–2 — regulatory status is documented; rapidly evolving.

Because these two come up constantly in searches, they deserve a direct answer.

CJC-1295 is not an FDA-approved drug. It has never been approved for any human indication in the US. It was among the peptides the FDA flagged with safety concerns and barred from 503A compounding in 2023, specifically over immunogenicity and impurity risks. So selling CJC-1295 for human use is illegal, and it is not a legally prescribable medicine in the way an approved drug is. The "is CJC-1295 legal" question usually comes from people who have seen it sold online as a "research peptide" — and that market is exactly the unapproved-drug gray zone described above.

BPC-157 sits in a similar but more dynamic spot. It is likewise not FDA-approved for human use and was on the restricted compounding list. As of 2026, it is one of the peptides the FDA moved out of the most-restrictive category and that the PCAC is reviewing for possible inclusion on the compounding bulks list (FDA, Pharmacy Compounding Advisory Committee (PCAC)). That review could change what licensed compounding pharmacies may legally prepare. It does not, today, make BPC-157 an approved drug, and it does not legalize buying research-grade BPC-157 powder online.

The contrast with GLP-1s is the clearest way to understand the landscape. Semaglutide and tirzepatide are legal because they went through the full approval process. CJC-1295, BPC-157, ipamorelin, and the rest have not — which is why they live in a market built on "research use only" disclaimers rather than prescriptions. The gap between a research-grade powder and a pharmaceutical-grade approved drug is enormous; we cover it in detail in research-grade vs pharmaceutical-grade peptides. And if you are evaluating any vendor, how to verify a peptide vendor lays out the checks that separate the careful sellers from the dangerous ones.

What are the actual risks of the gray market?

Evidence tier: 2 — established regulatory and quality-control reasoning.

The legal risk is the headline, but it is not the only one. When a product is unapproved, no agency has verified its identity, purity, dose, or sterility before it reaches you. The FDA has repeatedly documented serious harm — including infections and deaths — from poor-quality unapproved and compounded products, and it continues to find insanitary conditions during facility inspections (FDA, Understanding the Risks of Compounded Drugs).

For research-chemical peptides specifically, the practical risks stack up: the vial may not contain what the label claims, the stated concentration may be wrong, and there is no sterility guarantee for something people inject. Immunogenicity — the concern the FDA raised for several flagged peptides — is not theoretical; impurities in poorly made peptide products can provoke immune reactions. There is also no recourse: if a gray-market product harms someone, there is no manufacturer accountability, no recall system, and no regulatory backstop. These are the reasons the legality question and the safety question are really the same question wearing two hats.

Limitations

This is educational content, not legal or medical advice. Laws and FDA policy in this area are changing quickly, and specifics differ by jurisdiction and by individual circumstance.

• This is not legal advice. For decisions about importing, possessing, or using any substance, consult a qualified attorney and a licensed clinician about your specific situation.
• The rules are evolving. The FDA's compounding categories and PCAC reviews are actively changing in 2026; treat any specific status as a snapshot, not a permanent fact.
• "Legal to compound" is not "FDA-approved." Compounding eligibility says nothing about proven safety, efficacy, dosing, or benefit.
• State law adds another layer. Federal status is only part of the picture; states regulate pharmacies and practice independently.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Peptides are not simply "legal" or "illegal" in the US — the answer depends on the specific compound and what you do with it. A small set, led by the GLP-1 drugs semaglutide and tirzepatide, are fully legal FDA-approved prescription medicines. The large, popular world of "research peptides" — CJC-1295, BPC-157, TB-500, ipamorelin and the rest — consists of unapproved drugs that are illegal to sell for human use, regardless of "research use only" labeling. Importing them for personal use is, in most circumstances, also illegal: the FDA's personal-importation enforcement discretion is narrow and built for prescription medicines under a doctor's care, not for mail-order research chemicals. Pharmacy compounding under sections 503A and 503B is a separate, regulated channel, and the FDA's treatment of peptides like BPC-157 is actively shifting in 2026 — but eligibility to compound is not the same as approval, and none of it legalizes the online powder market. If you take one thing away: the legality question and the safety question are inseparable, because an unapproved product is one no one has checked.

Related on this site

• Peptide legal status (cornerstone)
• Peptide safety and sourcing guide
• Research-grade vs pharmaceutical-grade peptides
• How to verify a peptide vendor
• Where to buy peptides in the EU (2026)

References

• FDA. Personal Importation. U.S. Food and Drug Administration. fda.gov/industry/import-basics/personal-importation — the personal-use importation policy and enforcement-discretion conditions.
• FDA. Human Drug Compounding Laws. U.S. Food and Drug Administration. fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws — sections 503A and 503B under the DQSA.
• FDA. Understanding the Risks of Compounded Drugs. U.S. Food and Drug Administration. fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs — "not FDA-approved" framing and documented harms.
• FDA. Pharmacy Compounding Advisory Committee (PCAC). U.S. Food and Drug Administration. fda.gov/advisory-committees/pharmacy-compounding-advisory-committee-pcac — the committee reviewing peptide bulk substances.